Dash Bio (https://dash.bio), a Waltham, MA-based tech-first bioanalysis contract research organization, has raised $30M in Series A funding led by Oak HC/FT. The company leverages AI, robotics, and custom-built software to automate drug development bioanalysis, delivering assays up to 10x faster than the industry average with transparent fixed pricing. The capital will expand its 24,000 sq ft GLP-compliant lab and scale automated assay platforms.
Oak HC/FT Backs Bioanalysis Automation
The timing aligns with investor focus on drug development infrastructure. KCAS Bio raised $11M in June 2025. Dash Bio's approach — purpose-built automation from day one rather than retrofitting legacy workflows — targets the gap between AI-accelerated discovery and slow manual bioanalysis.
Manual Workflows Create Drug Development Delays
Traditional bioanalysis CROs deliver results in 4-8 weeks, creating bottlenecks as pharma invests heavily in AI for molecule design. The global CRO services market stands at $93.0B in 2026 and is projected to reach $140.3B by 2031 per MarketsandMarkets. The laboratory and bioanalytical CRO segment is $3.65B, growing at 6.5% CAGR to $5.0B by 2031 according to Mordor Intelligence.
Purpose-Built Automation Replaces Legacy Processes
Dash Bio built a proprietary lab operating system that drives robotic automation with built-in GLP/GCP compliance. This contrasts with incumbents such as BioAgilytix, which raised approximately $30.1M before its 2021 acquisition and operates at massive scale yet relies on traditional high-touch models. The company's platform supports ELISA, MSD, LC-MS, and qPCR with real-time sponsor visibility and outcome-based pricing.
As Andy Smith, partner at Oak HC/FT, noted:
"In less than two years, the Dash team has built a GLP-compliant, fully automated bioanalysis platform that the industry's largest drug developers are already adopting."
Oak HC/FT Leads With Healthcare Infrastructure Thesis
Oak HC/FT led the round, bringing its $7B+ AUM and focus on companies restructuring healthcare delivery systems. Existing investors Freestyle Capital and Swift Ventures participated again. The firm published a blog post titled "Unblocking the Drug Development Bottlenecks: Why We're Backing Dash Bio," signaling conviction in the platform approach.
$93B CRO Market Sees Tech-Native Entrants
The $93B CRO services market grows at 8.6% CAGR through 2031 amid rising complexity of biologics and cell therapies. Competitors like Solvias operate with undisclosed backing and traditional models, while Dash Bio positions itself as infrastructure for faster timelines. Lab automation in bioanalysis grows at 12.1% CAGR as regulatory bodies accept automated GLP workflows.
Ex-Moderna Founders Bring Pandemic-Speed Execution
CEO Dave Johnson previously served as Chief Data & AI Officer at Moderna. COO Ander Tallett led enterprise systems at Moderna and Resilience. CSO Ely Porter co-founded Rootpath. The team built the company from scratch with Moderna veterans who delivered mRNA vaccines at unprecedented speed.
Expansion Into NGS and Capacity Scaling Ahead
Dash Bio plans to expand into additional assay platforms such as NGS based on customer demand while scaling its Waltham facility and hiring across science, quality, and commercial roles.